Edition:
United Kingdom

Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

44.70USD
5:10pm BST
Change (% chg)

$0.69 (+1.57%)
Prev Close
$44.01
Open
$43.83
Day's High
$44.99
Day's Low
$43.80
Volume
27,531
Avg. Vol
357,918
52-wk High
$50.00
52-wk Low
$20.02

Latest Key Developments (Source: Significant Developments)

Arena Pharmaceuticals Reports Q1 Loss Per Share $0.80
Tuesday, 8 May 2018 

May 8 (Reuters) - Arena Pharmaceuticals Inc ::EXPECT TO INITIATE PHASE 3 STUDIES FOR RALINEPAG IN PULMONARY ARTERIAL HYPERTENSION IN SECOND HALF OF 2018.ARENA PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 REVENUE $1.8 MILLION.Q1 LOSS PER SHARE $0.80.Q1 REVENUE VIEW $2.8 MILLION -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $-0.68 -- THOMSON REUTERS I/B/E/S.  Full Article

Arena Pharmaceuticals To Offer 7.5 Mln Shares Of Its Common Stock In An Underwritten Public Offering
Tuesday, 20 Mar 2018 

March 20 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ARENA PHARMACEUTICALS INC - TO OFFER 7.5 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Arena Pharma, Everest Medicines Enter Into Development And Commercialization Partnership For Ralinepag And Etrasimod In China
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS AND EVEREST MEDICINES ENTER INTO DEVELOPMENT AND COMMERCIALIZATION PARTNERSHIP FOR RALINEPAG AND ETRASIMOD IN CHINA.ARENA PHARMACEUTICALS INC - C-BRIDGE CAPITAL HAS INVESTED $50 MILLION TO FUND EVEREST MEDICINES LIMITED.ARENA PHARMACEUTICALS - AS PER AGREEMENT, CO WILL RECEIVE AN UPFRONT PAYMENT OF $12 MILLION.ARENA PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, ARENA IS ELIGIBLE TO RECEIVE UP TO $212 MILLION IN DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS.  Full Article

Arena Pharmaceuticals reports Q3 loss per share $0.86
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Arena Pharmaceuticals Inc ::Arena Pharmaceuticals provides corporate update and reports third quarter 2017 financial results.Q3 loss per share $0.86.Q3 revenue $7.9 million.Q3 revenue view $5.5 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.67 -- Thomson Reuters I/B/E/S.Arena Pharmaceuticals Inc - ‍expect to complete full enrollment for etrasimod phase 2 study in ulcerative colitis this week​.Arena Pharmaceuticals Inc - ‍initiated etrasimod phase 2 study in primary biliary cholangitis​.  Full Article

Arena Pharmaceuticals, Eisai receive 'paragraph IV certification'
Thursday, 25 Aug 2016 

Arena Pharmaceuticals Inc : Co and Eisai Inc have received a 'paragraph IV certification' notification with respect to patents for Belviq . Notification is currently under investigation . Co and Eisai have 45 days from receipt of notification to file a patent infringement suit against ANDA filer .Patent infringement suit would result in stay of FDA approval of ANDA under statutory guidelines.  Full Article

Arena Pharmaceuticals reports Q2 loss per share $0.11
Monday, 8 Aug 2016 

Arena Pharmaceuticals Inc : Arena Pharmaceuticals reports second quarter 2016 financial results and provides corporate update . Q2 revenue $9.5 million versus I/B/E/S view $10.4 million . Q2 loss per share $0.11 .Q2 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Arena Pharmaceuticals Reports Q1 Loss Per Share $0.80

* EXPECT TO INITIATE PHASE 3 STUDIES FOR RALINEPAG IN PULMONARY ARTERIAL HYPERTENSION IN SECOND HALF OF 2018